SOURCE: Milestone Scientific, Inc.

milestone sc logo

December 16, 2014 08:30 ET

Milestone Scientific Appoints Steven F. Robins as President of Milestone Scientific and Milestone Medical

LIVINGSTON, NJ--(Marketwired - December 16, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced the appointment of Steven F. Robins as President of Milestone Scientific and Milestone Medical, exclusive licensee of Milestone Scientific's epidural and intra-articular instruments.

Mr. Robins has an extensive background in the healthcare industry and has been working with Milestone Scientific on a consulting basis since August of this year. Mr. Robins has held both General Management and Marketing positions at BAUSCH & LOMB, Johnson & Johnson and Pfizer.

Prior to joining Milestone, Mr. Robins was Chief Marketing Officer of BAUSCH + LOMB where he reversed declines in the flagship Vision Care division and contributed to the successful sale of Valeant Rx at approximately three times revenue. Previously, Mr. Robins was President of BAUSCH & LOMB Vision Care, North America where he oversaw commercial operations. He was instrumental in restoring the division's topline growth in its largest geographic region while substantially increasing EBITDA and gaining market share across the over-the-counter portfolio of products. Prior to Bausch & Lomb Mr. Robins was a Vice President and General Manager of Johnson & Johnson's Consumer Healthcare Business unit in Canada where he was responsible for successfully integrating key Pfizer consumer brands into J&J's portfolio. At Pfizer Consumer Healthcare, Mr. Robins held a series of roles including Group Marketing Director Upper Respiratory where he grew sales and profits in the Benadryl and Sudafed franchises during a time of significant regulatory challenges.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "Having demonstrated his skills during his career and since coming on board as a consultant to Milestone Scientific earlier this year, I am very pleased to announce Steve's new role as President of both Milestone Medical and Milestone Scientific. His business and marketing acumen combined with his leadership skills and team building ability will be integral to Milestone's next phase of growth as we embark upon rolling out our product pipeline of computer controlled injection systems to the global marketplace in the coming months and years."

Mr. Robins commented, "The applications for Milestone's innovative injection technologies are extensive and I am pleased to be in a position to drive the company forward on all fronts. During my four months as a consultant to the company, I have had an inside look at company operations and the market potential for Milestone's computer-controlled pressure sensing technology. The benefits to both patients and medical practitioners are significant and I look forward to getting the message out to the medical community and driving sales."

About Milestone Scientific Inc.
Milestone Scientific Inc. is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.


Contact Information

  • Contact:
    David Waldman or Klea Theoharis
    Crescendo Communications, LLC
    Tel: 212-671-1020